A Phase II Open-label Study With the Anti-PD-L1 Atezolizumab Monoclonal Antibody in Combination With Bevacizumab in Patients With Advanced Chemotherapy Resistant Colorectal Cancer and MSI-like Molecular Signature
Phase of Trial: Phase II
Latest Information Update: 02 Feb 2018
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 03 Nov 2017 Status changed from not yet recruiting to recruiting.
- 08 May 2017 Planned initiation date changed from 1 Mar 2017 to 1 Jul 2017.
- 08 Dec 2016 New trial record